Evaluating the oxidative stress in inflammation: Role of melatonin

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 16981-17004

  Sánchez, Aroha ^a   Calpena, Ana Cristina ^a   Clares, Beatriz ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antioxidant; Chronic diseases; Inflammation; Melatonin; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; C REACTIVE PROTEIN; CATALASE; CYCLOOXYGENASE 2; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN CONVERTING ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LINOLEIC ACID; MALONALDEHYDE; MELATONIN; PENTRAXIN 3; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; DNA DAMAGE; FIBROMYALGIA; GENE EXPRESSION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MENTAL DISEASE; MOUTH DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; CHEMISTRY; HEALTH; METABOLISM; NEOPLASM; PATHOLOGY;

EUKARYOTA;

ANIMALS; CHRONIC DISEASE; HUMANS; INFLAMMATION; MELATONIN; NEOPLASMS; ORAL HEALTH; OXIDATIVE STRESS;

EID: 84938117650     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160816981     Document Type: Review

References (168)

1. Cadenas, E.; Davies, K.J.A. Mitochondrial free radical generation, oxidative stress and aging. Free Radic. Biol. Med. 2000, 29, 222–230
2. Moniczewski, A.; Gawlik, M.; Smaga, I.; Niedzielska, E.; Krzek, J.; Przegaliński, E.; Pera, J.; Filip, M. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 1. Chemical aspects and biological sources of oxidative stress in the brain. Pharmacol. Rep. 2015, 67, 560–568
3. Nathan, C. Specificity of a third kind: Reactive oxygen and nitrogen intermediates in cell signalling. J. Clin. Investig. 2003, 111, 769–778
4. Halliwell, B. Reactive Oxygen species in living systems: Source, biochemistry and role in human disease. Am. J. Med. 1991, 91, 14-22
5. Kelley, E.E.; Khoo, N.K.H.H.; Hundley, N.J.; Malik, U.Z.; Freeman, B.A.; Tarpey, M.M. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radic. Biol. Med. 2010, 48, 493–498
6. Mc Cord, J. The evolution of free radicals and oxidative stress. Am. J. Med. 2000, 108, 652-659
7. Hartman, K.G.; Bortner, J.D.; Falk, G.W.; Yu, J.; Martín, M.G.; Rustgi, A.K.; Lynch, J.P. Modeling inflammation and oxidative stress in gastrointestinal disease development usign novel organotypic culture systems. Stem Cell Res. Ther. 2013, 4, 1-5
8. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 2007, 121, 2381–2386
9. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44–84
10. Baird, L.; Dinkova-Kostova, A.T. The cytoprotective role of the Keap1–Nrf2 pathway. Arch. Toxicol. 2011, 85, 241–272
11. Buelna-Chontal, M.; Zazueta, C. Redox activation of Nrf2 & NF-κB: A double end sword? Cell. Signal. 2013, 25, 2548–2557
12. Naik, E.; Dixit, V.M. Mitochondrial reactive oxygen species drive pro-inflammatory cytokine production. J. Exp. Med. 2011, 208, 417–420
13. Lee, K.M.; Kang, B.S.; Lee, H.L.; Son, S.J.; Hwang, S.H.; Kim, D.S.; Park, J.S.; Cho, H.J. Spinal NF-κB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur. J. Neurosci. 2004, 19, 3375-3381
14. Yadav, U.; Ramana, K.V. Regulation of NF-κB-induced inflammatory signaling by lipid peroxidation-derived aldehydes. Oxid. Med. Cell. Longev. 2013, 690545, 1-11
15. Ohnishi, S.; Ma, N.; Thanan, R.; Pinlaor, S.; Hammam, O.; Murata, M.; Kawanishi, S. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid. Med. Cell. Longev. 2013, 387014, 1-9
16. Aderem, A.; Ulevitch, R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406, 782–787
17. Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 2001, 1, 135–145
18. Babatunji, E.O.; Abiola, F.A.; Abidemi, P.K. Reactive oxygen species, apoptosis, antimicrobial peptides and human inflammatory diseases. Pharmaceuticals 2015, 8, 151-175
19. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic. Biol. Med. 2010, 49, 1603–1616
20. Smaga, I.; Niedzielska, E.; Gawlik, M.; Moniczewski, A.; Krzek, J.; Przegalin, E.; Pera, J.; Filip, M. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. Pharmacol. Rep.2015, 67, 569–580
21. Simoncini, C.; Orsucci, D.; Caldarazzo, E.; Siciliano, G.; Bonuccelli, U.; Mancuso, M. Alzheimer’s pathogenesis and its link to the mitochondrion. Oxid. Med. Cell. Longev. 2015, 803942, 1-8
22. Golpich, M.; Amini, E.; Hemmati, F.; Ibrahim, N.M.; Rahmani, B.; Mohamed, Z.; Raymond, A.A.; Dargahi, L.; Ghasemi, R.; Ahmadiani, A. Glycogen synthase kinase-3 β (GSK-3β) signaling: Implications for Parkinson’s disease. Pharmacol. Res. 2008, 97, 16-26
23. Ansari, M.A.; Roberts, K.N.; Scheff, S.W. Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injury. Free Radic. Biol. Med. 2008, 45, 443–452
24. Hawa, N.S.; Kamisah, Y.; Kamsiah, J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vasc. Pharmacol.2015, doi:10.1016/j.vph.2015.03.005
25. Pickup, J.C. Inflammation and activate innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27, 813-823
26. D’Aiuto, F.; Nibali, L.; Parkar, M.; Patel, K.; Suvan, J.; Donos, N. Oxidative stress, systemic inflammation, and severe periodontitis. J. Dent. Res.2010, 89, 1241-1246
27. Tucker, P.; Scanlan, A.; Dalbo, V.J. Chronic kidney disease influences multiple systems: Describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease. Oxid. Med. Cell. Longev. 2015, 806358, 1-8
28. Piechota-Polanczyk, A.; Fichna, J. Review article: The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch. Pharmacol. 2014, 387, 605–620
29. Mahad, D.H.; Trapp, B.D.; Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015, 14, 183–193
30. Park, Y.J.; Yoo, S.A.; Kim, W.U. Role of endoplasmic reticulum stress in rheumatoid arthritis pathogenesis. J. Korean Med. Sci. 2014, 29, 2-11
31. Balasubramaniyan, V. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J. Hepatol.2015, 27, 443-459
32. Sánchez-Domínguez, B.; Bullón, P.; Román-Malo, L.; Marín-Aguilar, F.; Alcocer-Gómez, E.; Carrión, A.M.; Sánchez-Alcazar, J.A.; Cordero, M.D. Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with Fibromyalgia. Mitochondrion 2015, 21, 69–75
33. Wallace, D.J.; Linker-Israeli, M.; Hallegua, D.; Silverman, S.; Silver, D.; Weisman, M.H. Cytokines play an aetiopathogenetic role in fibromyalgia: A hypothesis and pilot study. Rheumatology 2001, 40, 473-479
34. Macchi, M.M.; Bruce, J.N. Human pineal physiology and functional significance of melatonin. Front. Neuroendocrinol. 2004, 25, 177–195
35. Lerner, A.B.; Case, J.D.; Takahashi, Y. Isolation of melatonin and 5- methoxyindole-3-acetic acid from bovine pineal glands. J. Biol. Chem. 1960, 235, 1992–1997
36. Klein, D.C.; Moore, R.Y. Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: Control by the retinohy-pothalamic tract and the suprachiasmatic nucleus. Brain Res.1979, 174, 245–262
37. Axelrod, J.; Weissbach, H. Enzymatic O-methylation of N- acetylserotonin to melatonin. Science 1960, 131, 1312-1312
38. Reiter, R.J.; Paredes, S.D.; Manchester, L.C.; Tan, D.X. Reducing oxidative/nitrosative stress: A newly-discovered genre for melatonin. Crit. Rev. Biochem. Mol. Biol. 2009, 44, 175–200
39. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species. J. Pineal Res.2007, 42, 28–42
40. Dragicevic, N.; Copes, N.; O’Neal-Moffitt, G.; Jin, J.; Buzzeo, R.; Mamcarz, M.; Tan, J.; Cao, C.; Olcese, J.M.; Arendash, G.W., et al. Melatonin treatment restores mitochondrial function in Alzheimer’s mice: A mitochondrial protective role of melatonin membrane receptor signaling. J. Pineal Res.2011, 51, 75-86
41. Malhotra, S.; Sawhney, G.; Pandhi, P. The therapeutic potential of melatonin: A review of the science. Med. Gen. Med.2004, 6, 46
42. Arendt, J. Safety of melatonin in long-term use. J. Biol. Rhythm. 1997, 12, 673-681
43. Schernhammer, E.S.; Giobbie-Hurder, A.; Gantman, K.; Savoie, J.; Scheib, R.; Parker, L.M.; Chen, W.Y. A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes Control 2012, 23, 609-616
44. Luboshitzky, R.; Shen-Orr, Z.; Nave, R.; Lavi, S.; Lavie, P. Melatonin administration alters semen quality in healthy men. J. Androl. 2002, 23, 572-578
45. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444
46. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441, 431–436
47. Gilmore, T.D. Introduction to NF-κB: Players, pathways, perspectives. Oncogene 2006, 25, 6680–6684
48. Brasier, A.R. The NF-κB regulatory network. Cardiovacsc. Toxicol. 2006, 6, 111–130
49. Morgan, M.J.; Liu, Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011, 21, 103–115
50. Taniguichi, K.; Karin, M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 2014, 26, 54-74
51. Vlachostergios, P.J.; Papandreou, C.N. The Bmi-1/NF-κB/VEGF story: Another hint for protea-some involvement in glioma angiogenesis? J. Cell Commun. Signal. 2013, 7, 235–237
52. Steagall, R.J.; Daniels, C.R.; Dalal, S.; Joyner, W.L.; Singh, M.; Singh, K. Extracellular ubiquitin increases expression of angiogenic molecules and stimulates angiogenesis in cardiac microvascular endothelial cells. Microcirculation 2013, 21, 324–332
53. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 1989, 86, 2863–2867
54. Kedzierski, R.; Yanagisawa, M. Endothelin system: The double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 851–876
55. Grant, K.; Loizidon, M.; Taylor, I. Endothelin-1: A multi-functional molecule in cancer. Br. J. Cancer 2003, 88, 163–166
56. Rosano, L.; Spinella, F.; Bagnato, A. Endothelin 1 in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 2013, 13, 637–651
57. Stow, L.R.; Jacobs, M.E.; Wingo, C.S.; Cain, B.D. Endothelin-1 gene regulation. FASEB J. 2011, 25, 16–28
58. Leon, J.; Casado, J.; Sergio, M.; Jimenez Ruiz, S.M.; Zurita, M.S.; Gonzalez-Puga, C.; Rejon, J.D.; Gila, A.; Muñoz de Rueda, P.; Pavón, E.J., et al. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-κB. J. Pineal Res.2014, 56, 415–426
59. Dai1, M.; Cui, P.; Yu, M.; Han, J.; Li, H.; Xiu, R. Melatonin modulates the expression of VEGF and HIF-1α induced by CoCl2 in cultured cancer cells. J. Pineal Res. 2008, 44, 121–126
60. Bruick, R.K.; Mcknight, S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294, 1337–1340
61. Haddadi, G.H.; Fardid, R. Oral administration of melatonin modulates the expression of tumor necrosis factor-α (TNF-α) gene in irradiated rat cervical spinal cord. Rep. Pract. Oncol. Radiother. 2015, 20, 123–127
62. Farriol, M.; Venereo, Y.; Orta, X.; Castellanos, J.M.; Segovia-Silvestre, T. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J. Appl. Toxicol. 2000, 20, 21–24
63. Leon-Blanco, M.M.; Guerrero, J.M.; Reiter, R.J.; Calvo, J.R.; Pozo, D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J. Pineal Res.2003, 35, 204–211
64. Blask, D.E.; Dauchy, R.T.; Sauer, L.A.; Krause, J.A. Melatonin uptake and growth prevention in rat hepatoma 7288 CTC in response to dietary melatonin: Melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxydecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 2004, 25, 951–960
65. Padillo, F.J.; Ruiz-Rabelo, J.F.; Cruz, A.; Perea, M.D.; Tasset, I.; Montilla, P. Melatonin and celecoxib improve the outcomes in hamsterrs with experimental pancreatic cancer. J. Pineal Res. 2010, 49, 264-270
66. Ruiz-Rabelo, J.; Vázquez, R.; Arjona, A.; Perea, D.; Montilla, P.; Túnez, I. Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. Pancreas 2011, 40, 410-414
67. Ruiz-Rabelo, J.F.; Vázquez, R.; Perea, M.D.; Cruz, A.; González, R.; Romero, A. Beneficial propierties of melatonin in an experimental model of pancreatic cancer. J. Pineal Res. 2007, 43, 270–275
68. Lissoni, P.; Chilelli, M.; Villa, S.; Cerizza, L.; Tancini, G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J. Pineal Res.2003, 35, 12-15
69. Lissoni, P.; Rovelli, F.; Malugani, F.; Bucovec, R.; Conti, A.; Maestroni, G.J. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol. Lett. 2001, 22, 45-47
70. Todisco, M. Chronic lymphocytic leukemia: Long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. Cancer Biother. Radiopharm. 2009, 24, 353-355
71. Lissoni, P.; Vaghi, M.; Ardizzoia, A.; Malugani, F.; Fumagalli, E.; Bordin, V.; Fumagalli, L.; Bordoni, A.; Mengo, S.; Gardani, G.S., et al. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-α. In Vivo 2002, 16, 93-96
72. Todisco, M.; Casaccia, P.; Rossi, N. Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin’s lymphomas at advanced stage: Results of a phase II trial. Cancer Biother. Radiopharm. 2001, 16, 171-177
73. Lissoni, P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol. Biol.2007, 51, 201–204
74. Lissoni, P.; Barni, S.; Mandalà, M.; Ardizzoia, A. Paolorossi, F.; Vaghi, M.; Longarini, R. Malugani, F.; Tancini, G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur. J. Cancer 1999, 35, 1688-1692
75. Lissoni, P.; Brivio, O.; Brivio, F.; Barni, S.; Tancini, G.; Crippa, D.; Meregalli, S. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma J. Pineal Res. 1996, 21, 239-342
76. Flo, A.; Flo, V.; Calpena, A.C.; Clares, B. The role of antioxidant in sunscreens: The case of melatonin. In Sunscreens. Properties, Role in Skin Cancer Prevention and Health Effects; Sharp, S.H., Ed.; Nova Science Publishers, Inc.: New York, NY, USA, 2015; pp. 39-76
77. Bald, T.; Quast, T.; Landsberg, J.; Rogava, M.; Glodde N.; Lopez-Ramos, D.; Kohlmeyer, J.; Riesenberg, S.; van den Boorn-Konijnenberg, D.; Hömig-Hölzel, C.; et al. Ultraviolet-radiationinduced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014, 507, 109–113
78. Scheuer, C.; Pommergaard, H.C.; Rosenberg, J.; Gögenur, I. Melatonin’s protective effect against UV radiation: A systematic review of clinical and experimental studies. Photodermatol. Photoimmunol. Photomed. 2014, 30, 180-188
79. Sierra, A.F.; Ramírez, M.L.; Campmany, A.C.; Martínez, A.R.; Naveros, B.C. In vivo and in vitro evaluation of the use of a newly developed melatonin loaded emulsion combined with UV filters as a protective agent against skin irradiation. J. Dermatol. Sci. 2013, 69, 202-214
80. Offenbacher, S. Periodontal diseases: Pathogenesis. Ann. Periodontol. 1996, 1, 821–878
81. Smalley, J.W. Pathogenic mechanisms in periodontal disease. Adv. Dent. Res.1994, 8, 320–328
82. World Health Organization (WHO). Oral Health. Fact Sheet N° 318. Available online: http://www.who.int/mediacentre/factsheets/fs318/en/ (accessed on 11 July 2015).
83. Scardina, G.A.; Messina, P. Good oral health and diet. J. Biomed. Biotechnol. 2012, 720692, 1-8
84. Madani, A.H.; Dikshit, M.; Bhaduri, D.; Aghamolaei, T.; Moosavy, S.H.; Azarpaykan, A. Interaction of alcohol use and specific types of smoking on the development of oral cancer. Int. J. High Risk Behav. Addict. 2014, 1, 2120-2120
85. Macfarlane, G.J.; Zheng, T.; Marshall, J.R.; Boffetta, P.; Niu, S.; Brasure, J.; Merletti, F.; Boyle, P. Alcohol, tobacco, diet and the risk of oral cancer: A pooled analysis of three case-control studies. Eur. J. Cancer B 1995, 31, 181-187
86. Moreno-López, L.A.; Esparza-Gómez, G.C.; González-Navarro, A.; Cerero-Lapiedra, R.; González-Hernández, M.J.; Domı́nguez-Rojas, V. Risk of oral cancer associated with tobacco smoking, alcohol consumption and oral hygiene: A case-control study in Madrid, Spain. Oral Oncol. 2000, 36, 170-174
87. Preshaw, P.M.; Bissett, S.M. Periodontitis: Oral complication of diabetes. Endocrinol. Metab. Clin. N. Am. 2013, 42, 849-867
88. Irani, F.C.; Wassall, R.R.; Preshaw, P.M. Impact of periodontal status on oral health-related quality of life in patients with and without type 2 diabetes. J. Dent. 2015, 43, 506-511
89. Gustafsson, A.; Asman, B. Increased release of free oxygen radicals from peripheral neutrophils in adult periodontitis after Feδ-receptor stimulation. J. Clin. Periodontol. 1996, 23, 38–44
90. Waddington, R.J.; Moseley, R.; Embery, G. Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis. 2000, 6, 138–151
91. Avezov, K.; Reznick, A.; Aizenbud, D. Oxidative stress in the oral cavity: Sources and pathological outcomes. Respir. Physiol. Neurobiol. 2015, 209, 91-94
92. Firatli, E.; Unal, T.; Onan, U. Antioxidant activities of some chemotherapeutics. A possible mechanism in reducing gingival inflammation. J. Clin. Periodontol. 1994, 21, 680-683
93. Blasiak, J.; Kasznicki, J.; Drzewoski, J.; Pawlowska, E.; Szczepanska, J.; Reiter, R.J. Perspectives on the use of melatonin to reduce cytotoxic and genotoxic effects of methacrylate-based dental materials. J. Pineal Res. 2011, 51, 157–162
94. Gomez-Moreno, G.; Guardia, J.; Ferrera, M.J.; Cutando, A.; Reiter, R.J. Melatonin in diseases of the oral cavity. Oral Dis. 2010, 16, 242–247
95. Cutando, A.; Gomez-Moreno, G.; Arana, C.; Acuna-Castroviejo, D.; Reiter, R.J. Melatonin: Potential functions in the oral cavity. J. Periodontol. 2007, 78, 1094–1102
96. Almughrabi, O.M.; Marzouk, K.M.; Hasanato, R.M.; Shafik, S.S. Melatonin levels in periodontal health and disease. J. Periodontal Res. 2013, 48, 315–321
97. Srinath, R.; Acharya, A.B.; Thakur, S.L. Salivary and gingival crevicular fluid melatonin in periodontal health and disease. J. Periodontol. 2010, 81, 277–283
98. Gómez-Moreno, G.; Cutando-Soriano, A.; Arana, C.; Galindo, P.; Bolaños, J.; Acuña-Castroviejo, D. Melatonin expression in periodontal disease. J. Periodontal Res. 2007, 42, 536–540
99. Mutoh, N.; Tani-Ishii, N.; Tsukinoki, K.; Chieda, K.; Watanabe, K. Expression of toll-like receptor 2 and 4 in dental pulp. J. Endod. 2007, 33, 1183-1186
100. Liu, T.; Gao, Y.J.; Ji, R.R. Emerging role of Toll-like receptors in the control of pain and itch. Neurosci. Bull.2012, 28, 131-144
101. Ji-Guo, L.; Jia-Ji, L.; Zhao-Ling, W.; Wen-Ke, C.; Pei-Na, W.; Qian, J.; An-Sheng, Z.; Gao-Yi, W.; Guo-Xiong, Z; Long-Xing, N. Melatonin attenuates inflammation of acute pulpitis subjected to dental pulp injury. Am. J. Transl. Res. 2015, 7, 66-78
102. Adem, K.; Sumeyra, A.; Seckin, O.; Ummuhan, T.; Yıldıray, K.; Cenk, F.C.; Sinan, T. Immune modulatory and antioxidant effects of melatonin in experimental periodontitis in rats. Free Radic. Biol. Med. 2013, 55, 21–26
103. Gomez-Florit, M.; Ramis, J.M.; Monjo, M. Anti-fibrotic and anti-inflammatory properties of melatonin on human gingival fibroblasts in vitro. Biochem. Pharmacol. 2013, 86, 1784–1790
104. Nakade, O.; Koyama, H.; Ariji, H.; Yajima, A.; Kaku, T. Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J. Pineal Res.1999, 27, 106–110
105. Kao, M.P.C.; Ang, D.S.C.; Pall, A.; Struthers, A.D. Oxidative stress in renal dysfunction: Mechanisms, clinical sequelae and therapeutic options. J. Hum. Hypertens. 2010, 24, 1–8
106. Avery, S.V. Molecular targets of oxidative stress. Biochem. J. 2011, 434, 201–210
107. Berlett, B.S.; Stadtman, E.R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 1997, 33, 20313–20316
108. Halliwell, B.; Chirico, S.; Crawford, M.A.; Bjerve, K.S.; Gey, K.F. Lipid peroxidation: Its mechanism, measurement, and significance. Am. J. Clin. Nutr. 1993, 57, 715S–724S
109. Evans, M.D.; Dizdaroglu, M.; Cooke, M.S. Oxidative DNA damage and disease: Induction, repair and significance. Mutat. Res. 2004, 567, 1–61
110. Cooke, M.S; Evans, M.D.; Dizdaroglu, M.; Lunec, J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J. 2003, 17, 1195–1214
111. Turrens, J.F. Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 1997, 17, 3–8
112. Kurcer, Z.E.; Oguz, H.; Ozbilge, F.; Baba, N.; Aksoy, H.; Celik, H.; Cakir, H.; Gezen, M.R. Melatonin protects from ischemia/reperfusion-induced renal injury in rats: This effect is not mediated by proinflammatory cytokines. J. Pineal Res. 2007, 36, 172-178
113. Abraham, P.; Kolli, V.K.; Rabi, S. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem. Funct. 2010, 28, 426-433
114. Hara, M.; Yoshida, M.; Nishijima, H.; Yokosuka, M.; Ligo, M.; Ohtani-Kaneko, R.; Shimada, A.; Hasegawa, T.; Akama, Y.; Hirata, K. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J. Pineal Res.2001, 30, 129-138
115. Guan, X.; Dei-Anane, G.; Liang, R. Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation. J. Surg. Res. 2008, 146, 127–134
116. Lemasters, J.J.; Thurman, R.G. Reperfusion injury after liver preservation for transplantation. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 327–338
117. Li, Z.; Nickkholgh, A.; Yi, X.; Bruns, H.; Gross, M.L.; Hoffmann, K.; Mohr, E.; Zorn, M.; Büchler, M.W.; Schemmer, P. Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-κB and apoptosis after experimental kidney transplantation. J. Pineal Res. 2009, 46, 365–372
118. Bennett, R.M.; Jones, J.; Turk, D.C.; Russell, I.J.; Matallana, L. An internet survey of 2596 people with fibromyalgia. BMC Musculoskelet. Dis. 2007, 8, 27
119. Kalyan-Raman, U.P.; Kalyan-Raman, K.; Yunus, M.B. Muscle pathology in primary fibromyalgia syndrome: A light microscopic, histochemical and ultrastructural study. J. Rheumatol.1984, 11, 808–813
120. Lucas, H.J.; Brauch, C.M.; Settas, L. Fibromyalgia—New concepts of pathogenesis and treatment. Int. J. Immunopathol. Pharmacol. 2006, 19, 5–10
121. De Zanette, S.A.; Vercelino, R.; Laste, G.; Rozisky, J.R.; Schwertner, A.; Machado, C.B.; Xavier, F.; Custódio de Souza, I.C.; Deitos, A.; Torres, I.L.S., et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: A phase II, randomized, double-dummy, controlled trial. BMC Pharmacol. Toxicol. 2014, 15, 1-14
122. Hussain, S.A.; Al-Khalifa, I.I.; Jasim, N.A.; Gorial, F.I. Adjuvant use of melatonin for treatment of fibromyalgia. J. Pineal Res. 2011, 50, 267–271
123. Hanauer, S.B. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 2006, 12, 3–9
124. Geboes, K. Crohn’s disease, ulcerative colitis or indeterminate colitis—How important is it to differentiate? Acta Gastroenterol. Belg. 2001, 64, 197–200
125. Sartor, R.B. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3, 390–407
126. Danese, S.; Fiocchi, C. Ulcerative colitis. Engl. J. Med.2011, 365, 1713-1725
127. Williams, D.R.; Coller, J.A.; Corman, M.L.; Nugent, F.W.; Veidenheimer, M.C. Anal complications in Crohn’s disease. Dis. Colon Rectum 1981, 24, 22-24
128. Plauth, M.; Jenss, H.; Meyle, J. Oral manifestations of Crohn’s disease: An analysis of 79 cases. J. Clin. Gastroenterol. 1991, 13, 29-37
129. Seril, D.N.; Liao, J.; Yang, G.Y.; Yang, C.S. Oxidative stress and ulcerative colitis-associated carcinogenesis: Studies in humans and animal models. Carcinogenesis 2003, 24, 353–362
130. Boldeanu, M.V.; Siloşi, I.; Ghiluşi, M.; Cojocaru, M.; Biciuşcă, B.; Avrămescu, C.S.; Cojocaru, I.M.; Ciurea, T.; Albu, D.F.; Siloşi, C.A. Investigation of inflammatory activity in ulcerative colitis. Rom. J. Morphol. Embryol. 2014, 55, 1345–1351
131. Radema, S.A.; van Deventer S.J.; Cerami, A. Interleukin-1-β is expressed predominantly by enterocytes in experimental colitis. Gastroenterology 1991, 100, 1180–1186
132. Sakamoto, C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. J. Gastroenterol. 1998, 33, 618–624
133. Savchenko, A.S.; Inoue, A.; Ohashi, R. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol. Int. 2011, 61, 290–297
134. Souza, D.G.; Amaral, F.A.; Fagundes, C.T.; Coelho, F.M.; Arantes, R.M.; Sousa, L.P. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am. J. Pathol. 2009, 174, 1309–1318
135. Bottazzi, B.; Garlanda, C.; Salvatori, G. Jeannin, P.; Manfredi, A.; Mantovani, A. Pentraxins as a key component of innate immunity. Curr. Opin. Immunol. 2006, 18, 10–15
136. Gan, H.; Ouyang, Q.; Jia, D.; Xia, Q. Activation of nuclear factor-κB and its relationship with cytokine gene expression in colonic mucosa of ulcerative colitis patients. Chin. J. Int. Med. 2002, 41, 252-255
137. Jobin, C.; Hellerbrand, C.; Licato, L.L.; Brenner, D.A.; Sartor, R.B. Mediation by NF-κB of cytokine induced expression of intercellular adhesion molecule 1(ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 1998, 42, 779–787
138. Saigusa, S.; Araki, T.; Tanaka, K.; Hashimoto, K.; Okita, Y.; Fujikawa, H.; Okugawa, Y.; Toiyama, Y.; Inoue, Y.; Uchida, K., et al. Identification of patients with developing ulcerative colitis–associated neoplasia by nitrative DNA damage marker 8-nitroguanin expression in rectal mucosa. J. Clin. Gastroenterol. 2013, 47, 80-86
139. Heller, F.; Florian, P.; Bojarski, C.; Richter, J.; Christ, M.; Hillenbrand, B.; Schulzke, J.D. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129, 550-564
140. Gäbele, E.; Dostert, K.; Hofmann, C.; Wiest, R.; Schölmerich, J.; Hellerbrand, C.; Obermeier, F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J. Hepatol. 2011, 55, 1391-1399
141. Bellot, P.; Francés, R.; Such, J. Pathological bacterial translocation in cirrhosis: Pathophysiology, diagnosis and clinical implications. Liver Int. 2013, 33, 31-39
142. Jess, T.; Rungoe, C.; Peyrin-Biroulet, L. Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population based cohort studies. Clin. Gastroenterol. Hepatol. 2012, 10, 639–645
143. Trivedi, P.P.; Jena, G.B. Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: Investigation on possible mechanisms. Dig. Dis. Sci. 2013, 58, 3460–3474
144. Li, J.H.; Yu, J.P.; Yu, H.G.; Xu, X.M.; Yu, L.L.; Liu, J.; Luo, H.S. Melatonin reduces inflammatory injury through inhibiting NF-κB activation in rats with colitis. Mediat. Inflamm. 2005, 4, 185–193
145. Trivedi, P.P.; Jena, G.B.; Kumar, V. Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. Mol. Carcinog. 2015, doi:10.1002/mc.22274
146. Tahan, G.; Gramignoli, R.; Marongiu, F.; Aktolga, S.; Cetinkaya, A.; Tahan, V.; Dorko, K. Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig. Dis. Sci. 2011, 56, 715-720
147. Sayyed, H.G.; Jaumdally, R.J.; Idriss, N.K.; Dalia, A.; Blann, A. The effect of melatonin on plasma markers of inflammation and on expression of nuclear factor-κ β in acetic acid-induced colitis in the rat. Dig. Dis. Sci. 2013, 58, 3156-3164
148. Dong, W.G.; Mei, Q.; Yu, J.P.; Xu, J.M.; Xiang, L.; Xu, Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol. 2003, 9, 1307-1311
149. Chojnacki, C.; Wisniewska-jarosinska, M.; Walecka-kapica, E.; Klupinska, G.; Jaworek, J.; Chojnacki, J. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J. Physiol. Pharmacol. 2011, 62, 327-334
150. Klareskog, L.; Catrina, A.I.; Paget, S. Rheumatoid arthritis. Lancet 2009, 373, 659-672
151. Aho, K.; von Essen, R.; Kurki, P.; Palosuo, T.; Heliovaara, M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J. Rheumatol.1993, 20, 1278-1281
152. Nielen, M.M.; van Schaardenburg, D.; Reesink, H.W.; van de Stadt, R.J.; van der Horst-Bruinsma, I.E.; de Koning, M.H.; Habibuw, M.R.; Vandenbroucke, J.P.; Dijkmans, B.A. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum. 2004, 50, 380-386
153. Sokolove, J; Johnson, D.S.; Lahey, L.J.; Wagner, C.A.; Cheng, D.; Thiele, G.M.; Michaud, K.; Sayles, H.; Reimold, A.M.; Caplan, L., et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheum.2014, 66, 813-821
154. Isomaki, H. Long-term outcome of rheumatoid arthritis. Scand. J. Rheumatol. 1992, 95, 3–8
155. Pincus, T.; Callahan, L.F.; Sale, W.G.; Brooks, A.L.; Payne, L.E.; Vaughn, W.K. Severe functional declines, work disability, and increased mortality in seventy five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984, 27, 864-872
156. Lo Gullo, A.; Mandraffino, G.; Imbalzano, E.; Mamone, F.; Aragona, C.O.; D’Ascola, A.; Loddo, S.; Cinquegrani, A.; Alibrandi, A.; Mormina, E., et al. Toll-like receptor 3 and interleukin 1β expression in CD34+ cells from patients with rheumatoid arthritis: association with inflammation and vascular involvement. Clin. Exp. Rheumatol. 2014, 32, 922-929
157. Lo Gullo, A.; Mandraffino, G.; Sardo, M.A.; D’Ascola, A.; Mamone, F.; Loddo, S.; Alibrandi, A.; Imbalzano, E.; Mandraffino, R.; Mormina, E., et al. Circulating progenitor cells in rheumatoid arthritis: Association with inflammation and oxidative stress. Scand. J. Rheumatol. 2014, 43, 184-193
158. Hollan, I.; Nebuloni, M.; Bottazzi, B.; Mikkelsen, K.; Førre, O.T.; Almdahl, S.M.; Mantovani, A.; Fagerland, M.W.; Aukrust, P.; Meroni, P.L. Feiring Heart Biopsy Study Group. Pentraxin 3, a novel cardiovascular biomarker, is expressed in aortic specimens of patients with coronary artery disease with and without rheumatoid arthritis. Cardiovasc. Pathol. 2013, 22, 324-331
159. Van de Stadt, L.A.; de Vrieze, H.; Derksen, N.I.; Brouwer, M.; Wouters, D.; van Schaardenburg, D.; Wolbink, G.; Rispens, T. Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheum.2014, 66, 1133-1140
160. García-González, A.; Gaxiola-Robles, R.; Zenteno-Savín, T. Oxidative stress in patients with rheumatoid arthritis. Rev. Investig. Clin. 2015, 67, 46-53
161. Ali, A.M.; Habeeb, R.A.; El-Azizi, N.O.; Khattab, D.A.; Abo-Shady, R.A. Elkabarity, R.H. Higher nitric oxide levels are associated with disease activity in Egyptian rheumatoid arthritis patients. Rev. Bras. Reumatol. 2014, 54, 446-451
162. Maestroni, G.J.; Sulli, A.; Pizzorni, C.; Villaggio, B.; Cutolo, M. Melatonin in rheumatoid arthritis: Synovial macrophages show melatonin receptors. Ann. N. Y. Acad. Sci. 2002, 966, 271-275
163. Cutolo, M.; Villaggio, B.; Candido, F.; Valenti, S.; Giusti, M.; Felli, L.; Sulli, A.; Accardo, S. Melatonin influences interleukin-12 and nitric oxide production by primary cultures of rheumatoid synovial macrophages and THP-1 cells. Ann. N. Y. Acad. Sci. 1999, 2, 246-254
164. Bang, J.; Chang, H.W.; Jung, H.R.; Cho, C.H.; Hur, J.A.; Lee, S.I.; Choi, T.H.; Kim, S.H. Melatonin attenuates clock gene Cryptochrome1, which may aggravates mouse anti-type II collagen antibody-induced arthritis. Reumathol. Int. 2012, 32, 379-385
165. Kalpakcioglu, B.; Senel, K. The role of melatonin in rheumatic diseases. Infect. Disord. Drug Targets 2009, 9, 453-456
166. Forrest, C.M.; Mackay, G.M.; Stoy, N.; Stone, T.W.; Darlington, L.G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br. J. Clin. Pharmacol. 2008, 64, 517-526
167. Maestroni, G.J.; Otsa, K.; Cutolo, M. Melatonin treatment does not improve rheumatoid arthritis. Br. J. Clin. Pharmacol. 2008, 65, 797-798
168. Cardinali, D.P.; García, A.P.; Cano, P.; Esquifino, A.I. Melatonin role in experimental arthritis. Curr. Drug Targets Immune Endocr. Metab. Disord. 2004, 4, 1-10.